文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌新辅助化疗期间血栓预防可减少血栓栓塞与出血

Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
PubMed 文献 · BJU Int · 2024-07-03

该回顾性队列研究纳入1990至2021年间13个国家28个中心的4886例接受膀胱切除术的非转移性膀胱癌患者,采用逆概率加权分析评估新辅助化疗期间血栓预防对静脉血栓栓塞(VTE)和出血的影响。结果显示血栓预防组VTE风险(HR 0.32,95%CI 0.12-0.81;P=0.016)和出血风险(HR 0.03,95%CI 0.09-0.12;P<0.0001)均低于未预防组。作者认为血栓预防对VTE具有保护作用,应作为新辅助化疗期间的标准治疗。

要点

  • 4886例膀胱癌患者中,147例(3%)在一年内发生VTE,中位时间127天。
  • 131例(3%)在一年内发生出血事件,中位时间101天。
  • 血栓预防组VTE风险HR 0.32(95%CI 0.12-0.81;P=0.016),出血风险HR 0.03(95%CI 0.09-0.12;P<0.0001)。

核心结论

  • 作者认为,在该回顾性分析中,膀胱切除术前行新辅助化疗期间血栓预防的获益与其他恶性肿瘤随机试验数据一致。
  • 作者指出,数据提示血栓预防对VTE具有保护作用,应作为新辅助化疗期间的标准治疗。

研究设计与样本

  • 回顾性队列研究,纳入1990至2021年间13个国家28个中心的4886例接受膀胱切除术的非转移性膀胱癌患者。
  • 采用逆概率加权分析评估新辅助化疗期间血栓预防对VTE和出血的影响。

主要发现

  • 147例(3%)在一年内记录到VTE,发生于膀胱癌诊断后中位127天(IQR 82-198)。
  • 131例(3%)在一年内发生出血事件,发生于癌症诊断后中位101天(IQR 83-171)。
  • 逆概率加权分析中,与化疗期间未行血栓预防的患者相比,血栓预防组VTE风险更低(HR 0.32,95%CI 0.12-0.81;P=0.016)。
  • 逆概率加权分析中,与化疗期间未行血栓预防的患者相比,血栓预防组出血风险更低(HR 0.03,95%CI 0.09-0.12;P<0.0001)。

临床怎么用

  • 作者认为,血栓预防对VTE具有保护作用,应作为新辅助化疗期间的标准治疗。

局限性

  • 研究的回顾性性质是其主要局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the risk of venous thromboembolic events (VTEs) and bleeding with or without thromboprophylaxis during neoadjuvant chemotherapy in bladder cancer patients scheduled for radical cystectomy. MATERIALS AND METHODS: We conducted a retrospective cohort study in 4886 patients with non-metastatic bladder cancer undergoing cystectomy across 28 centres in 13 countries between 1990 and 2021. Inverse probability weighting analyses were performed to estimate the effect of thromboprophylaxis on VTE and bleeding. RESULTS: In 147 patients (3%) VTEs were recorded within the first year. These occurred a median (interquartile range [IQR]) of 127 (82-198) days after bladder cancer diagnosis. Bleeding events occurred in 131 patients (3%) within the first year. These occurred a median (IQR) of 101 (83-171) days after cancer diagnosis. In inverse probability weighting analyses, compared to patients without thromboprophylaxis during chemotherapy, patients with thromboprophylaxis had not only a lower risk of VTE (hazard ratio [HR] 0.32, 95% confidence interval [CI] 0.12-0.81; P = 0.016) but also a lower bleeding risk (HR 0.03, 95% CI 0.09-0.12; P <0.0001). The retrospective nature of the study was its main limitation. CONCLUSIONS: In this retrospective analysis, the benefit of thromboprophylaxis during neoadjuvant chemotherapy before cystectomy is in line with data from randomised trials in other malignancies. Our data suggest thromboprophylaxis is protective against VTEs and should be the standard of care during neoadjuvant chemotherapy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Antonelli L, Wendel-Garcia PD, Deforth M, et al. Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding. BJU Int. 2024. PMID: 38961717. doi:10.1111/bju.16444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。